

Summary of Investigation Results

Valemetostat tosilate

Non-proprietary name	Non-proprietary name	Brand name (marketing authorization holder)
Brand name	Valemetostat tosilate	Ezharmia Tablets 50 mg, 100 mg (Daiichi Sankyo Co., Ltd.)
Japanese market launch	December 2022	
Indications	<ul style="list-style-type: none"> ▪ Relapsed or refractory adult T-cell leukemia-lymphoma ▪ Relapsed or refractory peripheral T-cell lymphoma 	
Summary of revisions	Precautions for secondary malignancies should be added to the 8. IMPORTANT PRECAUTIONS.	
Investigation results and background of the revision	Cases involving secondary malignancies were evaluated. Although cases in which a causal relationship between valemetostat tosilate and secondary malignancy was reasonably possible have not been reported, as a result of consultation with expert advisors regarding the causality assessment of the cases and the necessity of revision of PRECAUTIONS, taking into consideration the circumstances surrounding drugs that inhibit enhancer of zeste homolog 2 (hereinafter referred to as "EZH2") as with valemetostat tosilate and the results of nonclinical studies of drugs that inhibit EZH2, the MHLW/PMDA concluded that revision of PRECAUTIONS was necessary.	
Reference: Number of cases* involving secondary malignancies reported in Japan	<p>A total of 11 cases have been reported to date (including 0 cases in which a causal relationship between the drug and the event was reasonably possible).</p> <p>A total of 2 deaths have been reported to date (including 0 cases in which a causal relationship between the drug and the death following the event was reasonably possible).</p>	

*: Among cases collected in the PMDA's safety database for drugs, cases corresponding to MedDRA Ver.28.1 SMQ (narrow) "Malignant tumours" as well as PTs "Myelodysplastic syndrome" and "Epstein-Barr virus associated lymphoproliferative disorder"

The expert advisors present at the Expert Discussion regarding the current investigation were nominated based on their conflict of interest declarations concerning the relevant products, pursuant to the "Rules for Convening Expert Discussions, etc., by the Pharmaceuticals and Medical Devices Agency" (PMDA Administrative Rule No. 20-8, dated December 25, 2008).